We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Angiotech Pharmaceuticals said it has entered into an exclusive license agreement
with CABG Medical to use the Canadian company's paclitaxel drug technology with
coronary bypass surgery.
The U.S. federal pharmaceuticals regulator has taken a significant step toward
the development of so-called personalized medicine, in which drugs would be
tailored to individuals based on their genetic profiles.
Cubist Pharmaceuticals announced that it has completed the issuance of $20 million
worth of Cubist common stock to Eli Lilly and Company in connection with the
previously announced royalty buy down transaction.
Adherex Technologies said that it will employ the services of another Triangle
drug company, Scynexis, as it tries to develop a way to administer drugs orally.
Curis has announced that it has achieved a development milestone in collaboration
with one of its corporate partners, Wyeth Pharmaceuticals, a division of Wyeth.
Demegen, Inc., a biotechnology company specializing
in the development of peptides for the treatment of infectious diseases, announced
it had granted a license to Pacgen Biopharmaceuticals Corporation for certain
Demegen peptides for prescription and over-the-counter pharmaceutical products
to treat oral diseases.
U.S. pharmaceutical companies looking to lower drug-development costs by contracting
with Chinese drugmakers for active pharmaceutical ingredients (APIs) need to
do so carefully, according to an industry expert, who warned that such partnerships
are not always cost-effective.
India's continued emergence as one of the world's leading drug-manufacturing
centers may be causing some U.S. firms to look over their shoulders, but Indian
drugmakers say their goal is to partner with their American counterparts, not
compete with them.